B. Metzler seel. Sohn & Co. Holding AG Buys New Position in Solventum Co. (NYSE:SOLV)

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Solventum Co. (NYSE:SOLV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,313 shares of the company’s stock, valued at approximately $231,000.

Several other hedge funds also recently added to or reduced their stakes in SOLV. Deseret Mutual Benefit Administrators acquired a new position in Solventum during the 2nd quarter valued at about $25,000. Hollencrest Capital Management acquired a new position in Solventum during the 2nd quarter valued at about $25,000. Partnership Wealth Management LLC acquired a new position in Solventum during the 2nd quarter valued at about $26,000. Richard W. Paul & Associates LLC acquired a new position in Solventum during the 2nd quarter valued at about $26,000. Finally, Family Firm Inc. acquired a new position in shares of Solventum in the second quarter valued at about $26,000.

Solventum Stock Performance

NYSE:SOLV opened at $71.58 on Tuesday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The stock has a 50 day moving average price of $70.52 and a 200 day moving average price of $62.35.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating on the stock. The Goldman Sachs Group increased their price objective on Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a report on Monday, August 12th. Morgan Stanley increased their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. BTIG Research began coverage on Solventum in a report on Thursday, September 5th. They issued a “neutral” rating on the stock. Finally, Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Solventum presently has an average rating of “Hold” and a consensus price target of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.